📊 BNR Key Takeaways
Is Burning Rock Biotech Ltd (BNR) a Good Investment?
Insufficient financial data available for fundamental analysis. SEC EDGAR filings contain no measurable income statement, balance sheet, or cash flow metrics. Cannot assess profitability, financial health, or growth quality without core financial statements.
Burning Rock’s 2024 fundamentals show a real improvement in operating discipline: net loss nearly halved year over year, operating cash burn fell sharply, and the company finished the year with a net-cash balance sheet and no long-term debt. The counterweight is growth quality: total revenue still declined, gross profit was essentially flat, and the path to sustainable profitability still depends more on cost reduction than on durable top-line expansion.
Why Buy Burning Rock Biotech Ltd Stock? BNR Key Strengths
- Company is publicly listed on Nasdaq with SEC reporting obligations
- Operates in medical laboratory services sector with potential market relevance
- SEC registration indicates regulatory oversight and disclosure requirements
- Losses narrowed materially in 2024, with net loss improving to RMB346.6 million from RMB653.7 million and operating loss improving to RMB357.6 million from RMB669.3 million
- Balance sheet remains solid, with RMB522.2 million of cash and restricted cash, current assets of RMB776.6 million versus current liabilities of RMB266.3 million, and no long-term borrowings
- Gross margin stayed strong at roughly 70%, and operating cash outflow improved to RMB92.3 million from RMB255.8 million, indicating better cash conversion and expense control
BNR Stock Risks: Burning Rock Biotech Ltd Investment Risks
- Complete absence of reported revenue, income, and asset data
- No financial metrics available to evaluate operational performance or solvency
- Potential non-reporting status or incomplete SEC filings preventing fundamental analysis
- Zero insider trading activity in past 90 days suggests limited stakeholder confidence signals
- Unable to assess cash burn rate, debt obligations, or liquidity position
- Revenue continued to contract, falling to RMB515.8 million in 2024 from RMB537.4 million in 2023, with services revenue declining materially
- The business is still deeply unprofitable, with operating margin around negative 69% and net margin around negative 67%, so self-funded growth is not yet established
- Growth mix is uneven, with product sales rising but higher-value services shrinking, which raises questions about demand durability and long-term margin quality
Key Metrics to Watch
- Revenue recognition and quarterly earnings reports
- Balance sheet assets, liabilities, and cash position
- Operating cash flow and capital expenditure trends
- Form 4 insider trading activity patterns
- SEC filing compliance and data completeness
- Whether total revenue returns to sustained year-over-year growth, especially stabilization in services revenue
- Quarterly/annual operating cash flow burn relative to the RMB522.2 million cash position and progress toward break-even
Burning Rock Biotech Ltd (BNR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BNR Profit Margin, ROE & Profitability Analysis
BNR vs Healthcare Sector: How Burning Rock Biotech Ltd Compares
How Burning Rock Biotech Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Burning Rock Biotech Ltd Stock Overvalued? BNR Valuation Analysis 2026
Based on fundamental analysis, Burning Rock Biotech Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Burning Rock Biotech Ltd Balance Sheet: BNR Debt, Cash & Liquidity
BNR Revenue Growth, EPS Growth & YoY Performance
BNR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Burning Rock Biotech Ltd (CIK: 0001792267)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BNR
What is the AI rating for BNR?
Burning Rock Biotech Ltd (BNR) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 40% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BNR's key strengths?
Claude: Company is publicly listed on Nasdaq with SEC reporting obligations. Operates in medical laboratory services sector with potential market relevance. ChatGPT: Losses narrowed materially in 2024, with net loss improving to RMB346.6 million from RMB653.7 million and operating loss improving to RMB357.6 million from RMB669.3 million. Balance sheet remains solid, with RMB522.2 million of cash and restricted cash, current assets of RMB776.6 million versus current liabilities of RMB266.3 million, and no long-term borrowings.
What are the risks of investing in BNR?
Claude: Complete absence of reported revenue, income, and asset data. No financial metrics available to evaluate operational performance or solvency. ChatGPT: Revenue continued to contract, falling to RMB515.8 million in 2024 from RMB537.4 million in 2023, with services revenue declining materially. The business is still deeply unprofitable, with operating margin around negative 69% and net margin around negative 67%, so self-funded growth is not yet established.
What is BNR's revenue and growth?
Burning Rock Biotech Ltd reported revenue of N/A.
Does BNR pay dividends?
Burning Rock Biotech Ltd does not currently pay dividends.
Where can I find BNR SEC filings?
Official SEC filings for Burning Rock Biotech Ltd (CIK: 0001792267) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BNR's EPS?
Burning Rock Biotech Ltd has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BNR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Burning Rock Biotech Ltd has a HOLD rating with 40% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BNR stock overvalued or undervalued?
Valuation metrics for BNR: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BNR stock in 2026?
Our dual AI analysis gives Burning Rock Biotech Ltd a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BNR's free cash flow?
Burning Rock Biotech Ltd's operating cash flow is N/A, with capital expenditures of N/A.
How does BNR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).